{
    "ticker": "PULM",
    "name": "Pulmatrix, Inc.",
    "description": "Pulmatrix, Inc. is a biotechnology company focused on developing innovative therapies for respiratory diseases. Founded in 2003, Pulmatrix leverages its proprietary iSPERSE technology to create inhaled therapeutics that aim to improve the delivery and efficacy of medications for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary disorders. The company is dedicated to addressing significant unmet medical needs through its unique formulation and delivery systems, which enhance the therapeutic potential of existing drugs while minimizing side effects. Pulmatrix's lead product candidates include PUR1900, an inhaled formulation of a potent antiviral agent designed to treat respiratory viral infections, and additional candidates targeting chronic respiratory diseases. The company is committed to advancing its pipeline through rigorous clinical trials and collaborations with other industry leaders. With a strong emphasis on research and development, Pulmatrix is poised to make a meaningful impact in the field of respiratory therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "2003",
    "website": "https://www.pulmatrix.com",
    "ceo": "Robert Clarke",
    "social_media": {
        "twitter": "https://twitter.com/Pulmatrix",
        "linkedin": "https://www.linkedin.com/company/pulmatrix"
    },
    "investor_relations": "https://www.pulmatrix.com/investors",
    "key_executives": [
        {
            "name": "Robert Clarke",
            "position": "CEO"
        },
        {
            "name": "Daryl J. DeMello",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Respiratory Therapeutics",
            "products": [
                "PUR1900"
            ]
        }
    ],
    "seo": {
        "meta_title": "Pulmatrix, Inc. | Innovative Respiratory Therapies",
        "meta_description": "Explore Pulmatrix, Inc., a biotechnology company developing innovative inhaled therapeutics for respiratory diseases. Learn about their unique technology and product pipeline.",
        "keywords": [
            "Pulmatrix",
            "Biotechnology",
            "Respiratory Diseases",
            "Inhaled Therapeutics",
            "PUR1900"
        ]
    },
    "faq": [
        {
            "question": "What is Pulmatrix known for?",
            "answer": "Pulmatrix is known for its development of inhaled therapeutics for respiratory diseases using its proprietary iSPERSE technology."
        },
        {
            "question": "Who is the CEO of Pulmatrix?",
            "answer": "Robert Clarke is the CEO of Pulmatrix, Inc."
        },
        {
            "question": "Where is Pulmatrix headquartered?",
            "answer": "Pulmatrix is headquartered in Lexington, Massachusetts, USA."
        },
        {
            "question": "What are Pulmatrix's main products?",
            "answer": "Pulmatrix's main product candidates include PUR1900 and other inhaled therapies targeting respiratory conditions."
        },
        {
            "question": "When was Pulmatrix founded?",
            "answer": "Pulmatrix was founded in 2003."
        }
    ],
    "competitors": [
        "VRTX",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "JNJ",
        "PFE"
    ]
}